The researchers evaluated the effectiveness of any adjuvant chemotherapy for patients aged ≥75 years with stage III colon cancer using information from four data sets: the SEER cancer registry linked to Medicare claims (SEER-Medicare), the New York State Cancer Registry linked to Medicare ...
CancerRisk factorsIn patients with colon cancer who undergo resection for potential cure, 40% to 60% have advanced locoregional disease and are classified as either stage II or stage III. The role of adjuvant therapy in stage III colon cancer is well defined. The results from the MOSAIC trial...
Dustin Deming, MD:When we’re thinking about adjuvant therapy for stage II and stage III colon cancer, we’re looking at what the risk is for this patient first. First for stage III, the node positivity is really what drives the risk for that particular patient population. John Marshall, ...
Howard S. Hochster, MD, FACP: I’ve given a lot of intraperitoneal chemotherapy in my career for ovarian cancer, and for gastric cancer, and some for colon cancer with FUDR, mainly for the GI [gastrointestinal] tumors. I think it’s probably not too effective. I don’t think warming ...
as a new adjuvant treatment for resectable microsatellites with highly unstable or mismatched repair protein defects (Msi-H/dmmr) colon cancer (CT4 or CN+ stage) has completed the first randomized, controlled, and multicenter clinical study (Neosshot) in patients with colon cancer (CT4 or CN+...
The aforementioned studies have all evaluated the use of 5-FU-based chemotherapy in stage II colon cancer. However, in the past 10 years, adjuvant therapy has evolved from 5-FU alone to the addition of oxaliplatin as the new standard adjuvant regimen. Irinotecan was also investigated in adjuvan...
Recently, capecitabine in combination with oxaliplatin has been approved for treatment of stage III colon cancer, providing the benefits of an oral fluoropyrimidine. Predictive markers for guidance of treatment have gained importance, particularly in stage II disease. Microsatellite instability, a well kno...
About a quarter of patients with locally advanced colon cancer (pT4) develop locoregional recurrence, including peritoneal metastases. The aim of this individual patient data meta-analysis (IPDMA) was to evaluate the efficacy of adjuvant hyperthermic intraperitoneal chemotherapy (HIPEC) with regard to ...
Really controversial settings, particularly settings that are actually increasingly common the more we look. Howard, I think we’re starting with you on this. What are you doing with earlier-stage colon cancer, particularly that stage II disease? How are you managing that?
Stage II colon cancer also has a good prognosis after operation alone and represents the most complicated and contentious area in decisions regarding the use of adjuvant chemotherapy. Stage III colorectal cancer (TanyN 1–2M 0) represents a group at a higher risk of recurrence, and this ...